NCT06485752View on ClinicalTrials.gov

Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2024

Primary Completion Date

February 4, 2025

Study Completion Date

February 4, 2025

Conditions
COVID-19
Interventions
BIOLOGICAL

tNIV 1 and Matrix-M Adjuvant

tNIV will be administered as a single 0.5 mL IM injection Day 0

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY

NCT06485752 - Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine | Biotech Hunter | Biotech Hunter